Association of Electrocardiographic P-Wave Markers and Atrial Fibrillation in Embolic Stroke of Undetermined Source.


Journal

Cerebrovascular diseases (Basel, Switzerland)
ISSN: 1421-9786
Titre abrégé: Cerebrovasc Dis
Pays: Switzerland
ID NLM: 9100851

Informations de publication

Date de publication:
2021
Historique:
received: 01 07 2020
accepted: 23 09 2020
pubmed: 15 12 2020
medline: 6 8 2021
entrez: 14 12 2020
Statut: ppublish

Résumé

Several P-wave indices are thought to represent underlying atrial remodeling and have been associated with ischaemic stroke even in the absence of atrial fibrillation (AF). However, the utility of these P-wave indices in predicting outcomes in patients with embolic stroke of undetermined source (ESUS) has not been studied. The aim of this study is to examine these different P-wave indices towards predicting new-onset AF and stroke recurrence in a cohort of patients with ESUS, thereby demonstrating the value of these electrocardiographic markers for stroke risk stratification. Between October 2014 and October 2017, consecutive patients diagnosed with ESUS were followed for new-onset AF and ischaemic stroke recurrence. The various P-wave indices, namely, the P-terminal force in the precordial lead V1 (PTFV1), P-wave duration, P-wave dispersion, interatrial blocks, and P-wave axis, were assessed on the initial electrocardiogram on presentation and studied for their relation to eventual AF detection and recurrent stroke. 181 ischaemic stroke patients with ESUS were recruited and followed up for a median duration of 2.1 years. An abnormal PTFV1 was associated with occult AF detection but not with recurrent ischaemic strokes. No significant association was observed between the other P-wave indices with either occult AF or stroke recurrence. PTFV1 is associated with AF detection but not recurrent strokes in ESUS patients and can be a useful electrocardiographic marker for further risk stratification in ESUS patients.

Sections du résumé

BACKGROUND
Several P-wave indices are thought to represent underlying atrial remodeling and have been associated with ischaemic stroke even in the absence of atrial fibrillation (AF). However, the utility of these P-wave indices in predicting outcomes in patients with embolic stroke of undetermined source (ESUS) has not been studied. The aim of this study is to examine these different P-wave indices towards predicting new-onset AF and stroke recurrence in a cohort of patients with ESUS, thereby demonstrating the value of these electrocardiographic markers for stroke risk stratification.
METHODS
Between October 2014 and October 2017, consecutive patients diagnosed with ESUS were followed for new-onset AF and ischaemic stroke recurrence. The various P-wave indices, namely, the P-terminal force in the precordial lead V1 (PTFV1), P-wave duration, P-wave dispersion, interatrial blocks, and P-wave axis, were assessed on the initial electrocardiogram on presentation and studied for their relation to eventual AF detection and recurrent stroke.
RESULTS
181 ischaemic stroke patients with ESUS were recruited and followed up for a median duration of 2.1 years. An abnormal PTFV1 was associated with occult AF detection but not with recurrent ischaemic strokes. No significant association was observed between the other P-wave indices with either occult AF or stroke recurrence.
CONCLUSION
PTFV1 is associated with AF detection but not recurrent strokes in ESUS patients and can be a useful electrocardiographic marker for further risk stratification in ESUS patients.

Identifiants

pubmed: 33311022
pii: 000512179
doi: 10.1159/000512179
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

46-53

Informations de copyright

© 2020 The Author(s) Published by S. Karger AG, Basel.

Auteurs

Tony Y W Li (TYW)

Internal Medicine Residency, National University Health System, Singapore, Singapore.

Leonard Leong L Yeo (LLL)

Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
Division of Neurology, Department of Medicine, National University Health System, Singapore, Singapore.

Jamie Sin Ying Ho (JSY)

Department of Medicine, University of Cambridge, Cambridge, United Kingdom.

Aloysius S Leow (AS)

Internal Medicine Residency, National University Health System, Singapore, Singapore.

Mark Y Chan (MY)

Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
Department of Cardiology, National University Heart Centre Singapore, Singapore, Singapore.

Mayank Dalakoti (M)

Department of Cardiology, National University Heart Centre Singapore, Singapore, Singapore.

Bernard P L Chan (BPL)

Division of Neurology, Department of Medicine, National University Health System, Singapore, Singapore.

Hock Luen Teoh (HL)

Division of Neurology, Department of Medicine, National University Health System, Singapore, Singapore.

Swee-Chong Seow (SC)

Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
Department of Cardiology, National University Heart Centre Singapore, Singapore, Singapore.

Pipin Kojodjojo (P)

Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
Department of Cardiology, National University Heart Centre Singapore, Singapore, Singapore.

Vijay K Sharma (VK)

Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
Division of Neurology, Department of Medicine, National University Health System, Singapore, Singapore.

Benjamin Y-Q Tan (BY)

Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore, benjamin_yq_tan@nuhs.edu.sg.
Division of Neurology, Department of Medicine, National University Health System, Singapore, Singapore, benjamin_yq_tan@nuhs.edu.sg.

Ching-Hui Sia (CH)

Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
Department of Medicine, University of Cambridge, Cambridge, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH